Codexis Inc (CDXS) Stock Price, Quote & News

Company Profile

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 421 8100

Website: www.codexis.com

Address:

200 Penobscot Drive, Redwood City, United States

rahmanoof Jun. 1 at 8:16 PM

$CDXS shoring rate fee is at the highest

0 · Reply

nlstbro May. 29 at 3:31 PM

$CDXS Need to Maintain $2.83 +!!!

0 · Reply

Jiggitus23 May. 29 at 3:13 PM

$CDXS

0 · Reply

nlstbro May. 29 at 1:07 PM

$CDXS

0 · Reply

Vwill33 May. 29 at 12:47 AM

$CDXS cmon

0 · Reply

nlstbro May. 28 at 2:39 PM

$CDXS $3 in the works!

0 · Reply

nlstbro May. 27 at 2:03 PM

$CDXS

0 · Reply

nlstbro May. 26 at 2:22 PM

$CDXS

0 · Reply

Jiggitus23 May. 22 at 4:21 PM

$CDXS I can feel the next leg coming

0 · Reply

Rolbox May. 20 at 2:41 PM

$CDXS

0 · Reply

Codexis reports Q1 EPS (10c), consensus (10c)

2026-05-07T22:51:14.000Z - 25 days ago

Codexis backs FY26 revenue view $72M-$76M, consensus $74.24M

May 7, 2026, 4:30 PM EDT - 25 days ago

Codexis Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 25 days ago

Codexis Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 25 days ago

Codexis Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 25 days ago

Codexis Reports First Quarter 2026 Financial Results

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

Codexis to share RNA manufacturing advances at TIDES USA

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Codexis Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Codexis Proxy statement: Proxy filing

Mar 11, 2026, 4:30 PM EDT - 2 months ago

Codexis Earnings Call Transcript: Q4 2025

Mar 11, 2026, 4:30 PM EDT - 2 months ago

Codexis Annual report: Q4 2025

Mar 11, 2026, 4:30 PM EDT - 2 months ago

Codexis Earnings release: Q4 2025

2026-03-11T20:25:25.000Z - 2 months ago

Codexis reports Q4 EPS 11c, consensus (4c)

2026-03-11T20:25:07.000Z - 2 months ago

Codexis sees FY26 revenue $72M-$76M, consensus $70.8M

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

2026-03-04T15:11:46.000Z - 3 months ago

Codexis announces agreement to manufacture 50 g siRNA

Mar 4, 2026, 10:06 AM EST - 3 months ago

Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

Mar 3, 2026, 11:50 AM EST - 3 months ago

Codexis Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 9:00 AM EST - 3 months ago

Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11

2026-02-10T14:05:57.000Z - 4 months ago

Codexis achieves ISO 9001:2015 certification

Feb 10, 2026, 9:00 AM EST - 4 months ago

Codexis Achieves ISO 9001:2015 Certification

2026-01-07T14:12:08.000Z - 5 months ago

Codexis signs evaluation agreement with Axolabs

Jan 7, 2026, 9:00 AM EST - 5 months ago

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

2025-11-10T14:11:19.000Z - 7 months ago

Codexis announces signing of lease for GMP manufacturing facility

Nov 10, 2025, 9:00 AM EST - 7 months ago

Codexis Announces Signing of Lease for GMP Manufacturing Facility

2025-11-06T22:35:34.000Z - 7 months ago

Codexis reports Q3 EPS (22c), consensus (13c)

Nov 6, 2025, 4:30 PM EST - 7 months ago

Codexis Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Codexis Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Codexis Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Codexis Slides: Q3 2025

2025-10-29T14:05:32.000Z - 7 months ago

Codexis, Nitto Denko Avecia enter evaluation agreement

Oct 29, 2025, 9:58 AM EDT - 7 months ago

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

Oct 23, 2025, 7:05 AM EDT - 7 months ago

Codexis to Report Third Quarter 2025 Financial Results on November 6

Sep 4, 2025, 3:55 PM EDT - 9 months ago

Codexis Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 9:00 AM EDT - 9 months ago

Codexis to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Codexis Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Codexis Quarterly report: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Codexis Earnings release: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Codexis Slides: Q2 2025

Aug 13, 2025, 4:05 PM EDT - 10 months ago

Codexis Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 10 months ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Codexis Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 8:00 AM EDT - 1 year ago

Codexis Transcript: Status Update

May 22, 2025, 8:00 AM EDT - 1 year ago

Codexis Press release: Status Update

2025-05-22T11:10:44.000Z - 1 year ago

Codexis presents data on ECO Synthesis platform at TIDES USA meeting

May 22, 2025, 7:00 AM EDT - 1 year ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 21, 2025, 4:05 PM EDT - 1 year ago

Codexis to Participate in Jefferies Global Healthcare Conference

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Slides: Q1 2025

2025-05-14T20:16:47.000Z - 1 year ago

Codexis reports Q1 EPS (25c), consensus (21c)

2025-05-14T20:16:39.000Z - 1 year ago

Codexis sees FY25 revenue $64M-$68M, consensus $65.67M

May 14, 2025, 4:05 PM EDT - 1 year ago

Codexis Reports First Quarter 2025 Financial Results

May 7, 2025, 7:00 AM EDT - 1 year ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Codexis Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Codexis Proxy statement: Proxy Filing

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

2025-04-01T11:21:28.000Z - 1 year ago

Codexis appoints Cynthia Collins to board of directors

2025-03-25T19:37:37.000Z - 1 year ago

Investors should buy Codexis following contract news, says Craig-Hallum

ALNY DHR

2025-03-24T11:20:13.000Z - 1 year ago

Codexis announces first revenue-generating contract for ECO Synthesis services

Mar 7, 2025, 4:05 PM EST - 1 year ago

Codexis Announces New Employment Inducement Grants

Mar 4, 2025, 1:10 PM EST - 1 year ago

Codexis Transcript: TD Cowen 45th Annual Healthcare Conference

2025-02-27T22:00:31.000Z - 1 year ago

Codexis reports Q4 EPS (13c), consensus (2c)

2025-02-27T22:00:23.000Z - 1 year ago

Codexis sees FY25 revenue $64M-$68M, consensus $66.61M

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Slides: Q4 2024

Feb 13, 2025, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 6, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Jan 16, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Christos Richards to Board of Directors

Dec 3, 2024, 11:00 AM EST - 1 year ago

Codexis Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 1:00 PM EST - 1 year ago

Codexis Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 19, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:30 AM EST - 1 year ago

Codexis Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 2:25 PM EST - 1 year ago

Codexis Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Codexis Transcript: Status Update

Nov 14, 2024, 4:30 PM EST - 1 year ago

Codexis Press release: Status Update

Nov 14, 2024, 4:05 PM EST - 1 year ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 12, 2024, 4:05 PM EST - 1 year ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 11, 2024, 4:05 PM EST - 1 year ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Slides: Q3 2024

Oct 24, 2024, 4:05 PM EDT - 1 year ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Sep 17, 2024, 11:30 AM EDT - 1 year ago

Codexis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Codexis Slides: Q2 2024

Jul 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 1, 2024, 4:05 PM EDT - 2 years ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Codexis Transcript: Jefferies Global Healthcare Conference

May 20, 2024, 4:05 PM EDT - 2 years ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 14, 2024, 6:00 AM EDT - 2 years ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings release: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Slides: Q1 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Codexis Registration statement: Registration Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Codexis Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Codexis Proxy statement: Proxy Filing

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 11, 2024, 7:05 AM EDT - 2 years ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Mar 4, 2024, 2:50 PM EST - 2 years ago

Codexis Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Annual report: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Earnings release: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Slides: Q4 2023

Feb 28, 2024, 4:05 PM EST - 2 years ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 8:05 AM EST - 2 years ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 20, 2024, 8:05 AM EST - 2 years ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 14, 2024, 4:05 PM EST - 2 years ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 13, 2024, 4:05 PM EST - 2 years ago

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Feb 1, 2024, 4:05 PM EST - 2 years ago

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Dec 27, 2023, 8:30 AM EST - 2 years ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Dec 13, 2023, 4:06 PM EST - 2 years ago

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Dec 13, 2023, 4:05 PM EST - 2 years ago

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

rahmanoof Jun. 1 at 8:16 PM

$CDXS shoring rate fee is at the highest

0 · Reply

nlstbro May. 29 at 3:31 PM

$CDXS Need to Maintain $2.83 +!!!

0 · Reply

Jiggitus23 May. 29 at 3:13 PM

$CDXS

0 · Reply

nlstbro May. 29 at 1:07 PM

$CDXS

0 · Reply

Vwill33 May. 29 at 12:47 AM

$CDXS cmon

0 · Reply

nlstbro May. 28 at 2:39 PM

$CDXS $3 in the works!

0 · Reply

nlstbro May. 27 at 2:03 PM

$CDXS

0 · Reply

nlstbro May. 26 at 2:22 PM

$CDXS

0 · Reply

Jiggitus23 May. 22 at 4:21 PM

$CDXS I can feel the next leg coming

0 · Reply

Rolbox May. 20 at 2:41 PM

$CDXS

0 · Reply

Fingerlickengood May. 20 at 2:24 PM

$CDXS https://ir.codexis.com/news-events/press-releases/detail/447/codexis-highlights-stereochemistry-advances-for-scalable-rna-manufacturing-at-tides-usa

0 · Reply

NVDAMillionaire May. 19 at 6:31 PM

$CDXS Really good write-up that perfectly summarizes CDXS's present situation. So if you want to bring your CDXS knowledge up to date or just discover CDXS, this is required reading. https://everyticker.com/quote/CDXS/analysis/enzymatic-rna-synthesis-codexis-s-2-billion-bet-on-replacing-chemistry-with-biology-nasdaq-cdxs

1 · Reply

Fingerlickengood May. 19 at 3:04 PM

$CDXS once this Iran situation is settled markst will rebound hatd. T-30 days imho!

0 · Reply

Fingerlickengood May. 19 at 2:46 PM

$CDXS Definitely a LOT of short covering here, they took advantage of the market this am. By the end of the week we might be back in the $2.8+ range. They have 3.5M+ shares short they still need to cover!

0 · Reply

Fingerlickengood May. 19 at 1:38 PM

$CDXS https://www.cnbc.com/amp/2026/04/27/lpa-drugs-from-novartis-amgen-and-eli-lilly-aim-to-prevent-heart-attacks.html

0 · Reply

Rolbox May. 19 at 3:12 AM

$CDXS

0 · Reply

SlvrShroud94 May. 18 at 10:55 PM

$CDXS so why are we here? Why shouldn’t I sell my entire position and put it on $IBRX or $SLS ?

6 · Reply

rahmanoof May. 18 at 9:46 PM

$CDXS that’s 104k buy after close looks good 😊

1 · Reply

Fingerlickengood May. 18 at 8:57 PM

$CDXS $NVS $IONS $AMGN "With phase 3 data from studies on Lp(a)s pelacarsen (TQJ230; Novartis) and olpasiran (Amgen) expected in the near term, quantifying the eligible population and projecting preventable events is a timely and policy-relevant contribution. If these therapies deliver even modest RRR in outcomes trials, the public health dividend could be substantial." -Pelacarsen is an experimental antisense oligonucleotide drug designed to lower lipoprotein(a) (Lp(a)) levels in patients with cardiovascular disease. It was developed by Ionis Pharmaceuticals and Novartis. -Olpasiran is an investigational small interfering RNA (siRNA) therapy developed by Arrowhead Pharmaceuticals and licensed worldwide by Amgen. Olpasiran is under investigation to reduce major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) concentrations. https://www.ajmc.com/view/more-than-5-million-us-adults-could-benefit-from-lp-a--targeted-therapies

0 · Reply

kubota2323 May. 18 at 8:03 PM

$CDXS

1 · Reply

kubota2323 May. 18 at 7:47 PM

$CDXS added 15000 Bags.

0 · Reply

Fingerlickengood May. 17 at 7:38 PM

$CDXS In 2024 when Millennium started buying millions of shares of Summit Therapeutics ($SMMT ), it was trading around the same price Codexis currently is, mid $2/shr range. Within six months of them buying, it topped $10/shr and an ATH of $25/shr about 15 months later. Very interesting! He is EXTREMELY sharp, he didn't turn $35M in 1989 to $77B by 2025 by making bad investments! www.aol.com/billionaire-israel-englander-just-quietly-110000785.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAEb8t7yQYu3d7ePi8Fl7vAL65OuVneOYDCDeR74lMz_9BfUarw_XGyUY37b_uD2RQmjdXpoGoXXgW_Z_6PyJ6rTAyz-Gbp3WnAtyI5vADEUOzNj5hBOxiqFeDKMJvhHI7dwiuuzKPuETmkvYlSRKVzT5QFfeDUDXANkvju5viZUg

0 · Reply

Market Cap	251.79M
Revenue (ttm)	70.39M
Net Income (ttm)	-43.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-62.47%
Debt to Equity Ratio	0.94

Volume	276,652
Avg Vol	1,264,092
Day's Range	N/A - N/A
Shares Out	90.90M
Stochastic %K	84%
Beta	2.52
Analysts	Strong Sell
Price Target	$6.58